EP0503050A4 - Hybrid growth factors - Google Patents

Hybrid growth factors

Info

Publication number
EP0503050A4
EP0503050A4 EP19910918221 EP91918221A EP0503050A4 EP 0503050 A4 EP0503050 A4 EP 0503050A4 EP 19910918221 EP19910918221 EP 19910918221 EP 91918221 A EP91918221 A EP 91918221A EP 0503050 A4 EP0503050 A4 EP 0503050A4
Authority
EP
European Patent Office
Prior art keywords
growth factors
hybrid growth
hybrid
factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910918221
Other versions
EP0503050A1 (en
Inventor
Jonathan I Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US58995890A priority Critical
Priority to US589958 priority
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of EP0503050A1 publication Critical patent/EP0503050A1/en
Publication of EP0503050A4 publication Critical patent/EP0503050A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5403IL-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
EP19910918221 1990-09-28 1991-09-26 Hybrid growth factors Withdrawn EP0503050A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US58995890A true 1990-09-28 1990-09-28
US589958 1990-09-28

Publications (2)

Publication Number Publication Date
EP0503050A1 EP0503050A1 (en) 1992-09-16
EP0503050A4 true EP0503050A4 (en) 1994-07-06

Family

ID=24360286

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910918221 Withdrawn EP0503050A4 (en) 1990-09-28 1991-09-26 Hybrid growth factors

Country Status (8)

Country Link
EP (1) EP0503050A4 (en)
JP (1) JPH05502463A (en)
AU (2) AU8735991A (en)
CA (1) CA2069746A1 (en)
IE (1) IE913426A1 (en)
PT (1) PT99107A (en)
WO (1) WO1992006116A1 (en)
ZA (1) ZA9107766B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
EP0546124B2 (en) * 1990-08-29 2003-04-23 Genetics Institute, LLC Multidomain hematopoiesis stimulators
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
EP1361273A3 (en) * 1992-11-24 2004-02-11 G.D. SEARLE & CO. Interleukin-3 (IL-3) multiple mutation polypeptides
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1995028427A1 (en) * 1994-04-15 1995-10-26 Imclone Systems Incorporated Chimeric interleukin-3/mutein interleukin-6 lymphokine
ITFI940106A1 (en) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Hybrid Molecule Formula gm-csf-the-EPO or EPO-the-gm-csf for stimolaz ion erythropoietic
IT1271688B (en) * 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa hybrid molecules for anticancer treatment their preparation and their use in pharmaceutical compositions
AT346096T (en) * 1995-04-26 2006-12-15 Kyowa Hakko Kogyo Kk G-csf tpo fusion proteins
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
JP3764487B2 (en) * 1996-09-20 2006-04-05 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Method of measuring the in vitro biological activity of erythropoietin
AU721196B2 (en) * 1996-10-25 2000-06-29 G.D. Searle & Co. Circularly permuted erythropoietin receptor agonists
KR100497423B1 (en) * 1996-10-25 2005-07-07 지.디. 썰 엘엘씨 Multi-functional chimeric hematopoietic receptor agonists
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
DE69726571T2 (en) * 1997-09-01 2004-11-04 Aventis Pharma Deutschland Gmbh Recombinant human erythropoietin with a favorable glycosylation
AU2866599A (en) * 1998-02-17 1999-08-30 Hyseq, Inc. A novel interleukin-3 and uses thereof
BR9917606A (en) * 1998-11-06 2002-12-31 Bio Sidus S A Procedure for purification of recombinant human erythropoietin from cell culture supernatants and recombinant human erythropoietin obtained with this procedure
MXPA02011303A (en) 2000-05-15 2003-04-25 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivate.
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
WO2006055260A2 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
RU2573909C2 (en) 2010-03-04 2016-01-27 Пфенекс Инк. Method for obtaining soluble recombinant interferon protein without denaturation
PL2552949T3 (en) 2010-04-01 2017-01-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
WO2014021386A1 (en) 2012-07-31 2014-02-06 旭化成イーマテリアルズ株式会社 Epoxy resin composition, epoxy resin, and cured article
LT6161B (en) 2013-09-27 2015-06-25 Uab Profarma Fused proteins of granulocyte colony-stimulating factor with other partners of growh factor, preferably with stem cell factor, and method of preparation thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001039A1 (en) * 1988-07-20 1990-02-08 Immunex Corporation Nonglycosylated human interleukin-3 compositions
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
WO1991002754A1 (en) * 1989-08-22 1991-03-07 Immunex Corporation Fusion proteins comprising gm-csf and il-3
WO1991007988A1 (en) * 1989-12-01 1991-06-13 Amgen Inc. Megakaryocyte production
WO1992004455A1 (en) * 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203672B (en) * 1982-05-12 1989-02-15 Harvard College hybrid protein comprising protein fragments linked by peptide bonds and relative fusion gene composition containing such protein
US4935352A (en) * 1985-10-21 1990-06-19 Takeda Chemical Industries, Ltd. Expression vector for animal cell line and use thereof
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA1339346C (en) * 1986-08-01 1997-08-26 Ian Allister Ramshaw Recombinant chimeric vaccine
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001039A1 (en) * 1988-07-20 1990-02-08 Immunex Corporation Nonglycosylated human interleukin-3 compositions
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
WO1991002754A1 (en) * 1989-08-22 1991-03-07 Immunex Corporation Fusion proteins comprising gm-csf and il-3
WO1991007988A1 (en) * 1989-12-01 1991-06-13 Amgen Inc. Megakaryocyte production
WO1992004455A1 (en) * 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. TANIKAWA ET AL: "Effects of recombinant granulocyte colony-stimulatinfg-factor (rG-CSF) and recombinant granulocyte-macrophage colony-stimulating-factor (rGM-CSF) on acute radiation hematopoietic injury in mice", EXPERIMENTAL HEMATOLOGY, vol. 17, 1989, pages 883 - 888 *
See also references of WO9206116A1 *

Also Published As

Publication number Publication date
CA2069746A1 (en) 1992-03-29
AU8735991A (en) 1992-04-28
ZA9107766B (en) 1993-03-29
PT99107A (en) 1992-08-31
WO1992006116A1 (en) 1992-04-16
AU1157695A (en) 1995-04-13
IE913426A1 (en) 1992-04-08
EP0503050A1 (en) 1992-09-16
JPH05502463A (en) 1993-04-28

Similar Documents

Publication Publication Date Title
DE69118889D1 (en) R(+)-terazosin
DE69130944D1 (en) Endocurietherapie
DE69125712D1 (en) Hüftprothese
GB2246776B (en) Oxorapamycin
DE69129497D1 (en) Restecholöschung
DE69127457D1 (en) 6-0-methylerythromycin a-derivat
DE4190756D2 (en) Mikrotom
DE59109027D1 (en) Arylpyridazinone
GB2248494B (en) Multi-airconditioner
GB2251034B (en) Shrouded aerofoils
DE69125374D1 (en) Endonukleasen
GB2237709B (en) Hybrid network
AU7937791A (en) Culture bag
HK1013298A1 (en) Hybrid immunoglobulins
EP0804214A4 (en) Growth differentiation factor-6
DE69126781D1 (en) Fabry-perot-modulator
GB9023243D0 (en) Containers
GB9115349D0 (en) Electrical-optical hybrid connector
IL112712A (en) Piperazino- and morpholino-amidines
LU90935I2 (en) Azopt-brinzolamide
EP0440282A3 (en) Sensormatrix
PL167617B1 (en) Hygenic suspensorium
HU9300874D0 (en) Storage for tins
IL99984D0 (en) Chimeric fibroblast growth factors
HUT60120A (en) Spine-fixture

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 19920430

AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/62

A4 Despatch of supplementary search report
AK Designated contracting states:

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report

Effective date: 19951123

18D Deemed to be withdrawn

Effective date: 19960405